Lennox-Gastaut症候群（LGS）：全球市場展望、流行病學、競爭格局和市場預測報告（32個主要市場），2025-2035年

市場概覽

• 預計義大利LGS市場將從2025年的5,000萬美元成長到2035年的1.1億美元。
• 以下因素推動市場成長：
• 擴大新型抗癲癇療法的應用
• 標靶治療的持續發展
• 未來的發展取決於能夠減少持續性癲癇發作並改善患者預後的治療方法。

Lennox-Gastaut症候群（LGS）概述

Lennox-Gastaut症候群（LGS）是嚴重的、高度難治性的發育性癲癇腦病變，通常發病於幼兒期，一般在3至5歲之間。此疾病的通用表現型終點是由多種潛在原因造成的，包括腦結構畸形、周產期缺氧缺血性損傷、基因突變或由領先的West症候群進展而來。 LGS的主要特徵是三種電臨床症狀：持續存在多種藥物難治性癲癇發作類型（特別是整體強直性發作、肌張力喪失性跌倒和非典型失神發作）、進行性性認知障礙以及發作間期腦電圖（EEG）異常，其特徵為清醒時瀰漫性慢波棘慢波複合波和睡眠時整體陣發性快速活動（GPFA）。治療普遍需要採用複雜的聯合治療，使用多種抗癲癇藥物，尤其需要合併使用標靶治療，例如Clobazam、Rufinamide、純化大麻二酚和氟苯丙胺。氟苯丙胺因其獨特的減少跌倒發作和支持日常執行功能的能力而被列為首要治療方案。非常重要的是，標準治療流程嚴格避免使用傳統的鈉通道阻斷劑，例如苯妥英和Carbamazepine，因為它們反而會加重強直性癲癇發作。非藥物療法，例如生酮飲食、迷走神經刺激和姑息性胼胝體切除手術，對於最大限度地減少創傷相關損傷和最佳化長期生存率仍然非常重要。

主要亮點

• 據預測，德國確診的Lennox-Gastaut 症候群（LGS）病例數將從2025年的6,787 例增加到2035年的6,849 例。
• LGS 是一種罕見且嚴重的癲癇性腦病變，其特徵是多種類型的癲癇發作和認知障礙。
• 儘管抗癲癇藥物已經問世，但許多患者仍然遭受難治性癲癇的困擾。
• 目前仍有大量未被滿足的需求，即需要能夠持續抑制癲癇發作並改善生活品質的治療方法。

市場定義：

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

形式和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於MicrosoftExcel）
• 流行病學資料（MS Excel，互動式工具）
• 高層洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 如何最佳化在 32個市場（北美、歐洲、中東、亞太、非洲和南美/拉丁美洲）的藥物開發和生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東

提及公司

• Epygenix
• Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
• SK Life Science, Inc.
• NeuroPace
• Zogenix, Inc.
• Jazz Pharmaceuticals
• Longboard Pharmaceuticals

目錄

第1章 主要調查結果和分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章 流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者族群。
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 依藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要療法 - 概述及關鍵意見領袖見解
• 新興療法
• 重點
• 值得關注的後期新興療法 - 概述、市場上市預期和關鍵意見領袖見解
• 值得關注的早期管道

第6章 未滿足的需求與目標產品分析

• 主要未滿足需求及新興療法的未來成就
• TPP分析與KOL展望

第7章 監理與償付環境

第8章 附錄

Global Lennox-Gastaut Syndrome (LGS) Market Outlook

Thelansis's "Global Lennox-Gastaut Syndrome (LGS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Lennox-Gastaut Syndrome treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Lennox-Gastaut Syndrome (LGS) Overview

Lennox-Gastaut syndrome (LGS) is a severe, highly refractory developmental and epileptic encephalopathy that classically manifests in early childhood between the ages of three and five. The disease represents a shared phenotypic endpoint resulting from a heterogeneous array of underlying etiologies, including structural brain malformations, perinatal hypoxic-ischemic injury, genetic mutations, or evolution from preceding West syndrome. LGS is fundamentally defined by a pathognomonic electroclinical triad: a relentless mixture of multiple drug-resistant seizure types (most prominently generalized tonic seizures, atonic drop attacks, and atypical absences), progressive cognitive impairment, and hallmark interictal electroencephalographic (EEG) abnormalities characterized by diffuse slow spike-and-wave complexes during wakefulness and generalized paroxysmal fast activity (GPFA) during sleep. Management universally requires complex polytherapy with broad-spectrum anti-seizure medications, specifically integrating targeted agents like clobazam, rufinamide, purified cannabidiol, and fenfluramine, which is highly prioritized for its unique ability to reduce drop attacks and support everyday executive functioning. Crucially, standard algorithms strictly avoid traditional sodium channel blockers like phenytoin and carbamazepine, as they paradoxically aggravate tonic seizures. Non-pharmacological therapies-including the ketogenic diet, vagus nerve stimulation, and palliative corpus callosotomy-remain integral to minimizing trauma-related injuries and optimizing long-term survival.

Key Highlights

• In Germany, diagnosed Lennox-Gastaut Syndrome (LGS) cases are projected to increase from **6,787 in 2025 to 6,849 by 2035**.
• LGS is a rare, severe epileptic encephalopathy associated with multiple seizure types and cognitive impairment.
• Despite available antiseizure therapies, many patients continue to experience treatment-resistant seizures.
• Significant unmet need remains for therapies that provide sustained seizure control and improve quality of life.

Market Overview

• The Italy LGS market is projected to grow from **$50M in 2025 to $110M by 2035**.
• Market growth is driven by:
• Increasing adoption of novel antiseizure therapies
• Ongoing development of targeted treatment options
• Future growth will depend on therapies capable of achieving durable seizure reduction and improved patient outcomes.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle Ea

Companies Mentioned

• Epygenix
• Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
• SK Life Science, Inc.
• NeuroPace
• Zogenix, Inc.
• Jazz Pharmaceuticals
• Longboard Pharmaceuticals

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)